Ticker Details
Corvus Pharmaceuticals, Inc. Common Stock Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
IPO Date:	March 21, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.32B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 3.67%
Avg Daily Range (30 D):	$0.47 | 3.10%
Avg Daily Range (90 D):	$0.52 | 3.77%

Institutional Daily Volume
Avg Daily Volume:	.64M
Avg Daily Volume (30 D):	.94M
Avg Daily Volume (90 D):	2.41M

Trade Size
Avg Trade Size (Sh.):	178
Avg Trade Size (Sh.) (30 D):	64
Avg Trade Size (Sh.) (90 D):	96

Institutional Trades
Total Institutional Trades:	331
Avg Institutional Trade:	$1.83M
Avg Institutional Trade (30 D):	$2.57M
Avg Institutional Trade (90 D):	$2.03M
Avg Institutional Trade Volume:	.2M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.62M
Avg Closing Trade (30 D):	$2.84M
Avg Closing Trade (90 D):	$2.84M
Avg Closing Volume:	253.64K

News

Feb 2, 2026 @ 5:48 PM Momentum Is Just Starting for These 3 Rapid-Growth... Source: Nathan Reiff

Jan 23, 2026 @ 10:00 PM Corvus Pharmaceuticals Announces Closing of Upsize... Source: Corvus Pharmaceuticals, Inc.

Jan 22, 2026 @ 3:53 AM Corvus Pharmaceuticals Announces Pricing of Upsize... Source: Na

Oct 17, 2025 @ 2:00 PM Corvus Pharmaceuticals Announces Presentation of I... Source: Corvus Pharmaceuticals

Jul 10, 2025 @ 5:00 PM Interleukin-2 Inhibitors Clinical Trial Pipeline A... Source: Delveinsight

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.19	$-.15	$-.19
Diluted EPS	$-.53	$-.15	$-.53
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-15.28M	$-12.32M	$-15.28M
Operating Income / Loss	$-42.97M	$-12.22M	$-42.97M
Cost of Revenue
Net Cash Flow	$-4.16M	$1.71M	$-4.16M
PE Ratio